Centaurus Financial Inc. Boosts Stake in Johnson & Johnson $JNJ

Centaurus Financial Inc. lifted its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 49.5% in the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 12,384 shares of the company's stock after acquiring an additional 4,103 shares during the period. Centaurus Financial Inc.'s holdings in Johnson & Johnson were worth $3,145,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Blueline Advisors LLC purchased a new position in Johnson & Johnson during the fourth quarter valued at $25,000. Matrix Trust Co increased its stake in shares of Johnson & Johnson by 56.2% in the 2nd quarter. Matrix Trust Co now owns 150 shares of the company's stock worth $38,000 after acquiring an additional 54 shares in the last quarter. E Fund Management Hong Kong Co. Ltd. lifted its position in Johnson & Johnson by 946.7% during the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 157 shares of the company's stock valued at $32,000 after acquiring an additional 142 shares during the period. MidAtlantic Capital Management Inc. bought a new stake in Johnson & Johnson during the fourth quarter worth about $37,000. Finally, Semmax Financial Advisors Inc. grew its holdings in Johnson & Johnson by 55.0% in the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company's stock worth $31,000 after purchasing an additional 72 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have weighed in on JNJ shares. Citigroup raised their target price on shares of Johnson & Johnson from $285.00 to $298.00 and gave the company a "buy" rating in a research note on Wednesday, July 8th. Freedom Capital upgraded Johnson & Johnson from a "hold" rating to a "strong-buy" rating in a research note on Thursday, July 16th. Leerink Partners raised Johnson & Johnson from a "market perform" rating to an "outperform" rating and set a $265.00 target price on the stock in a report on Wednesday, May 13th. HSBC set a $290.00 price target on Johnson & Johnson and gave the stock a "buy" rating in a research report on Monday, July 6th. Finally, Morgan Stanley increased their price objective on shares of Johnson & Johnson from $284.00 to $294.00 and gave the company an "overweight" rating in a research report on Thursday, July 16th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson presently has an average rating of "Moderate Buy" and an average target price of $272.83.

Insider Activity

In related news, EVP Kathryn E. Wengel sold 10,000 shares of the stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the transaction, the executive vice president owned 114,288 shares in the company, valued at $27,560,551.20. This represents a 8.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Vanessa Broadhurst sold 23,054 shares of the firm's stock in a transaction that occurred on Monday, July 20th. The stock was sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the completion of the sale, the executive vice president owned 23,003 shares in the company, valued at $5,779,963.81. This represents a 50.06% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 97,569 shares of company stock worth $25,476,044. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Stock Down 0.0%

Johnson & Johnson stock opened at $275.12 on Tuesday. Johnson & Johnson has a 12 month low of $173.33 and a 12 month high of $281.07. The stock has a fifty day simple moving average of $262.32 and a two-hundred day simple moving average of $245.30. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44. The firm has a market cap of $663.01 billion, a price-to-earnings ratio of 31.88, a PEG ratio of 2.63 and a beta of 0.24.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.84 by $0.06. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The firm had revenue of $25.31 billion for the quarter, compared to the consensus estimate of $25.06 billion. During the same period in the prior year, the company posted $2.77 earnings per share. The company's quarterly revenue was up 6.6% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Equities analysts predict that Johnson & Johnson will post 11.61 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be paid a dividend of $1.34 per share. The ex-dividend date is Tuesday, August 25th. This represents a $5.36 annualized dividend and a yield of 1.9%. Johnson & Johnson's dividend payout ratio is currently 62.11%.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.